Manages central (cranial) diabetes insipidus. ANDA 74888, held by Meitheal. Desmopressin Acetate.
As of Nov 16, 2026, ANDA 74888 (Desmopressin Acetate), held by Meitheal, was first approved by FDA on Oct 15, 1997, with 6 approved supplements and 0 published complete response letters.
Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 15, 1997 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desmopressin Acetate0.004MG/ML · injectable;injection | Desmopressin Acetate | Rx |
| Aug 28, 2024 | Supplement 30Labeling · Standard review | Approved | None posted |
| Jul 25, 2019 | Supplement 26Labeling · Standard review | Approved | None posted |
| Jul 25, 2019 | Supplement 27Labeling · Standard review | Approved | None posted |
| Mar 27, 2009 | Supplement 9Labeling | Approved | None posted |
| Mar 25, 2002 | Supplement 2Labeling | Approved | None posted |
| Aug 10, 1998 | Supplement 1Manufacturing | Approved | None posted |
| Oct 15, 1997 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters